Characterization of the inhibition of P4501A2 by furafylline

References

• Aoyama T., Korzekwa K., Nagata K., Gillette J., Gelboin H. V., Gonzalez F. J. Estradiol metabolism by complementary deoxyribonucleic acid-expressed human cytochrome P450s. Endocrinology 1990; 126: 3101–3106
   PubMed Web of Science ®Google Scholar
• Berthou F., Flinois J.-P., Ratanasavanh D., Beaune P., Riche C., Guillouzo A. Evidence for the involvement of several cytochromes P-450 in the first steps of caffeine metabolism by human liver microsomes. Drug Metabolism and Disposition 1991; 19: 561–567
   PubMed Web of Science ®Google Scholar
• Burke M. D., Thompson S., Elcombe C. R., Halpert J., Haaparanta T., Mayer R. T. Ethoxy-, pentoxy, and benzyloxyphenoxazones and homologues: a series of substrates to distinguish between different induced cytochromes P-450. Biochemical Pharmacology 1985; 34: 3337–3345
   PubMed Web of Science ®Google Scholar
• Butler M. A., Iwasaki M., Guengerich F. P., Kadlubar F. K. Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proceedings of the National Academy of Sciences, USA 1989; 86: 7696–7700
   PubMed Web of Science ®Google Scholar
• Cambell M. E., Grant D. M., Inaba T., Kalow W. Biotransformation of caffeine, paraxanthine, theophylline and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome(s) P-450 in human liver microsomes. Drug Metabolism and Disposition 1987; 15: 237–249
   PubMedGoogle Scholar
• Deluca J. G., Dysart G. R., Rasnick D., Bradley M. O. A direct, highly sensitive assay for cytochrome P-450 catalyzed O-deethylation using a novel coumarin analog. Biochemical Pharmacology 1988; 37: 1731–1739
   PubMed Web of Science ®Google Scholar
• Dirven H. A. A. M., Peters J. G. P., Gibson G. G., Peters W. H. M., Jongeneelen F. J. Lauric acid hydroxylase activity and cytochrome P450 IV family proteins in human liver microsomes. Biochemical Pharmacology 1991; 42: 1841–1844
   PubMed Web of Science ®Google Scholar
• Disterlath L. M., Reilly P. E. B., Martin M. V., Davis G. G., Wilkinson G. R., Guengerich F. P. Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. Journal of Biological Chemistry 1985; 260: 9057–9067
   PubMedGoogle Scholar
• Eugster H.-P., Probst M., Würgler F. E., Sengstag C. Caffeine, estradiol and progesterone interact with human CYP1A1 and CYP1A2. Drug Metabolism and Disposition 1993; 21: 43–49
   PubMed Web of Science ®Google Scholar
• Fuhr U., Doehmer J., Battula N., Wölfel C., Kudla C., Keita Y., Staib A. H. Biotransformation of caffeine and theophylline in mammalian cell lines genetically engineered for expression of single cytochrome P450 isoforms. Biochemical Pharmacology 1992; 43: 225–235
   PubMed Web of Science ®Google Scholar
• Funae Y., Imaoka S. Purification and characterization of liver microsomal cytochrome P-450 from untreated male rats. Biochimica et Biophysica Acta 1987; 926: 349–358
   PubMed Web of Science ®Google Scholar
• Kunze K. L., Trager W. F. Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. Chemical Research in Toxicology 1993; 6: 649–656
   PubMed Web of Science ®Google Scholar
• Leakey T. E. B. Simultaneous analysis of theophylline, caffeine and eight of their metabolic products in human plasma by gradient high performance liquid chromatography. Journal of Chromatography 1990; 507: 199–220
   PubMed Web of Science ®Google Scholar
• Leatherbarrow R. J. Grafit Version 3.0. Erithacus Software Ltd, StainesUK 1992
   Google Scholar
• Maurice M., Emiliani S., Dalet-Beluche I., Derancourt J., Lange R. Isolation and characterisation of a cytochrome P450 of the IIA subfamily from human liver microsomes. European Journal of Biochemistry 1991; 200: 511–517
   PubMedGoogle Scholar
• Meier U. T., Kronbach T., Meyer U. A. Assay of mephenytoin metabolism in human liver microsomes by high-performance liquid chromatography. Analytical Biochemistry 1985; 151: 286–291
   PubMed Web of Science ®Google Scholar
• Mintrs J. O., Smith K. J., Robson R. A., McManus M. E., Veronese M. E., Birkett D. J. Tolbutamide hydroxylation by human liver microsomes kinetic characterisation and relationship to other cytochrome P-450 dependent xenobiotic oxidations. Biochemical Pharmacology 1988; 37: 1137–1144
   Google Scholar
• Nelson D. R., Tetsuya K., Waxman D. J., Guengerich F. P., Estabrook R. W., Feyereisen R., Gonzalez F. J., Coon M. J., Gunsalus I. C., Gotoh O., Okuda K., Nebert D. W. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA and Cell Biology 1993; 12: 1–51
   PubMed Web of Science ®Google Scholar
• Peter R., Böcker R., Beaune P. H., Iwasaki M., Guengerich F. P., Yang C. S. Hydroxylation of chloroxazone as a specific probe for human liver cytochrome P-450IIE1. Chemical Research in Toxicology 1990; 3: 566–573
   PubMed Web of Science ®Google Scholar
• Rich K. J., Murray B. P., Lewis I., Rendell N. B., Davies D. S., Godderham N. J., Boobis A. R. N-hydroxy-MeIQx is the major microsomal oxidation product of the dietary carcinogen MeIQx with human liver. Carcinogenesis 1992; 13: 2221–2226
   Google Scholar
• Sesardic D., Boobis A. R., Murray B. P., Murray B. P., Murray S., Segura J., De La Torre R., Davies D. S. Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. British Journal of Clinical Pharmacology 1990; 29: 651–663
   PubMed Web of Science ®Google Scholar
• Smith P. K., Krohn R. I., Hermanson G. T., Mallia A. K., Gartner F. H., Provenzano M. D., Fujimoto E. K., Goeke N. M., Olson B. J., Klenk C. Measurement of protein using bicinchoninic acid. Analytical Biochemistry 1985; 150: 76–85
   PubMed Web of Science ®Google Scholar
• Tarrús E., Cami J., Roberts D. J., Spickett R. G. W., Celdram E., Segura J. Accumulation of caffeine in healthy volunteers treated with furafylline. British Journal of Clinical Pharmacology 1987; 23: 9–18
   PubMed Web of Science ®Google Scholar
• Tipton K. F. Enzyme kinetics in relation to enzyme inhibitors. Biochemical Pharmacology 1973; 22: 2933–2941
   PubMed Web of Science ®Google Scholar
• Valero F., De La Torre R., Boobis A. R., Murray S., Segura J. Assay of caffeine metabolism in vitro by human liver microsomes using radio-high-performance liquid chromatography. Journal of Pharmacology and Biomedical Analysis 1990; 8: 783–787
   PubMedGoogle Scholar
• Veronese M. E., Doecke C. J., Mackenzie P. I., McManus M. E., Miners J. O., Rees D. L. P., Gasser R., Meyer U. A., Birkett D. J. Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. Biochemical Journal 1993; 289: 533–538
   PubMed Web of Science ®Google Scholar
• Waxman D. J., Lapenson D. P., Aoyama T., Gelboin H. V., Gonzalez F. J., Korzekwa K. Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s. Archives of Biochemistry and Biophysics 1991; 290: 160–166
   PubMed Web of Science ®Google Scholar
• Wrighton S. A., Stevens J. C., Becker G. W., Vandenbranden M. Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Archives of Biochemistry and Biophysics 1993; 306: 240–245
   PubMed Web of Science ®Google Scholar
• Yamano S., Tatsuno J., Gonzalez F. J. The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry 1990; 29: 1322–1329
   PubMed Web of Science ®Google Scholar
• Zanger U. M., Vilbois F., Hardwick J., Meyer U. A. Absence of hepatic cytochrome P450buf1 causes genetically deficient debrisoquine oxidation in man. Biochemistry 1988; 27: 5447–5454
   PubMed Web of Science ®Google Scholar